The main eligibility criteria for weight in the STEP 1, 3, 4, and 5 trials were BMI 30 kg/m 2 or BMI 27 kg/m 2 with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or CVD), while patients in STEP 2 had to have a BMI 27 kg/m 2 and T2D
Besides the well-known targets such as the inhibition of the mTOR signaling pathway, several additional metformin and phenformin targets (e.g., mGPDH, ATF3, STAT3, GSK3, cyclins) have been identified in other cancers (Thakur et al., 2019)
Nayan Patel to deliver the only topical absorbable Glutathione on the market, with a unique patented technology that ensures unrivaled and maximum absorbability, strength, and effectiveness
I.De BruijnF
Influence of DSIP on human sleep stages